Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

03.13.17

EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.

WALTHAM, Mass., March 13, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases...
Read more
02.23.17

EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update

Waltham, Mass., Feb. 23, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...
Read more
02.21.17

VALEANT PHARMACEUTICALS AND EYEGATE ENTER INTO LICENSING AGREEMENT FOR EGP-437 COMBINATION PRODUCT IN POST-OPERATIVE PAIN AND INFLAMMATION IN OCULAR SURGERY PATIENTS

Novel Approach Offers Eye Care Practitioners Delivery Alternative for Post-Operative Therapeutic Regimens LAVAL, QUEBEC and WALTHAM, MA – FEBRUARY 21, 2017 - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:...
Read more
02.06.17

EyeGate Pharmaceuticals Announces Executive Promotions

Sarah Romano named Interim Chief Financial Officer; Lisa Brandano and Carol Assang promoted to Vice President, Clinical Operations and Director, Clinical Operations, respectively WALTHAM, Mass., February 06, 2017 — EyeGate...
Read more
01.30.17

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

Company Plans to Continue Development with Next Controlled Trial Q2 2017 WALTHAM, Mass., January 30, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company...
Read more
01.24.17

EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference

WALTHAM, Mass., January 24, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more
01.23.17

EyeGate Pharma Awarded Canadian Patent for Proprietary Iontophoretic Formulation and Use of the Formulation for Ocular Delivery of Dexamethasone Phosphate

Patent Further Strengthens EyeGate’s Global IP Protection for Lead Product Candidate, EGP-437 WALTHAM, Mass., January 23, 2017 -- Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical...
Read more
01.09.17

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Jan. 09, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...
Read more